Others titles

  • VAERS Identification 2022
  • Vaccine Adverse Events 2022
  • Vaccine Adverse Event Reporting System VAERS Data 2022

Keywords

  • Vaccine Adverse Event Reporting System VAERS Data
  • VAERS Data
  • VAERS Data 2022
  • Vaccination Reporting System 2022
  • FDA Vaccine Reports
  • CDC Vaccine Reports
  • Vaccine Side Effects

Vaccine Adverse Event Reporting System 2022

The Vaccine Adverse Event Reporting System (VAERS) 2022 was created by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) to receive reports about adverse events that may be associated with vaccines. No prescription drug or biological product, such as a vaccine, is completely free from side effects.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Standard End User License Agreement (“EULA”) applies to customers of John Snow Labs Inc. (as defined below), using any product of John Snow Labs Inc. on John Snow Labs Marketplace as defined below (hereinafter referred to “you”) and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading, installing, and/or using (as applicable) any Product of John Snow Labs (as defined below), you automatically agree to be bound by, and use our Products in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE PURCHASING, INSTALLING OR USING OUR PRODUCTS MADE AVAILABLE ON JOHN SNOW LABS MARKETPLACE.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of our Products after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“John Snow Labs Data Library” means a data library located at https://www.johnsnowlabs.com;

“Products” means products and services of John Snow Labs that you download and use from listings in John Snow Labs Data Library;

Important Notice

By installing and using our Products, you acknowledge that the use of the Products can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use the Products for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Products can be used by an individual, business or other legal entity, or both. If you are entering into this EULA, or using the Products, on behalf of a company or other legal entity, you represent that you have the authority to bind such entity to this EULA, in which case “you” shall refer to such entity.

In the event you have entered into a separate written agreement with John Snow Labs regarding the Products that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all.

Your Access and Use

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, license to install, access to, modify, and use of, the Products worldwide (subject to applicable export laws) during the term of this EULA (as described below) solely for research, private study and personal use of Products.

This license is personal to you, and you may not resell our Products, permit other users access to our Products through your account. Your right to use our Products is limited by all terms and conditions set forth in this EULA.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Products, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Products are protected by applicable intellectual property laws, including United States copyright law and international treaties.

Except for the foregoing license, you have no other rights in the Products and you may not modify, edit, copy, reproduce, create derivative works of, reverse engineer, alter, enhance or in any way exploit the Products in any manner. If you breach any of this EULA, the above license will terminate automatically.

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of the Products. You are responsible for end users’ use of your content and the Products. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and the Products by such end user. We do not provide any support or services to end users unless we have a separate agreement with you or an end user obligating us to provide such support or services.

Restrictions

You will access or use our Products solely via John Snow Labs Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. reproduce, modify, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of any of our Products or its technological features or measures;
  2. rent, lease, sell, resell, loan, distribute, or sublicense access to any of our Products;
  3. circumvent or disable any security or technological features or measures of our Products;
  4. use our intellectual property rights without our express prior written authorization;
  5. use our Products for more than one trial period, unless the trial period is extended by John Snow Labs’ prior written permit;
  6. use our Products with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of the Products;
  7. store, copy, modify, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on our Products (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  8. use any automated tool (e.g., robots, spiders) to access or use our Products, or to store, copy, modify, distribute, or resell any Content;
  9. circumvent or disable any rights management, usage rules, or other security features of our Products;
  10. use our Products in a manner that overburdens, or that threatens the integrity, performance, or availability of, our Products; or
  11. remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Fees and Taxes

Your use of the Products is subject to our fees. All fees are given on our website https://www.johnsnowlabs.com. Except as set forth in this EULA, the fees are non-refundable. We are entitled to revise our fees from time to time.

The fees exclude any federal, state or local taxes, VAT, GST, or similar taxes. You are responsible for identification and payment of all taxes as required by applicable law.

Term and Termination

This EULA will become effective as of the date of your order of Products and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use our Products, if you or your end user’s use of the Products:

  1. is in breach of this EULA;
  2. poses a security risk to our Products;
  3. could adversely impact our systems, the Products or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use our Products, if you fail to perform your payment obligations, or you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

We may also suspend or terminate your right to use our Products without any reason upon a relevant 30 days’ written notice to you and will refund the unused fees pre-paid by you for access to the Products for the affected time period (if any). Where your access is suspended or terminated by the breach of this EULA or applicable laws, John Snow Labs will will not provide, or be liable for, any refund.

You will cease use of the Products during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Support

If applicable to your Product, John Snow Labs will provide you with the support services. If you use a trial access, support services are excluded. Under this EULA, our support services exclude any installation, training, maintenance services (including any error corrections, bug fixes, or new releases), technical assistance, consulting services, or other services of any kind. Such services are provided at John Snow Labs’ discretion.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Access to our Products

We do not provide you with the equipment to access our Products. You are responsible for all fees charged by third parties related to your access and use of our Products (e.g., charges by Internet service providers).

You are responsible for monitoring your use of the Products, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of the Products for auditing purposes.

You also certify that you are legally permitted to use the Products, and take full responsibility for the selection and use of the Products. This EULA is void where prohibited by law, and the right to use the Products is revoked in such jurisdictions. John Snow Labs makes no claim that the Products may be lawfully used outside of the United States. If you use the Products from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Our Products may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using our Products (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using our Products, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

The Products, including software, is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to the Products or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on our Products are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of our Products, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs and may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in our Products are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF THE PRODUCTS IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of the Products; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of the Products will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Products. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about our Products or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, meaning that reports about adverse events are not automatically collected, but require a report to be filed to VAERS. VAERS reports can be submitted voluntarily by anyone, including healthcare providers, patients, or family members. Reports vary in quality and completeness. They often lack details and sometimes can have information that contains errors. About 85-90% of vaccine adverse event reports concern relatively minor events, such as fevers or redness and swelling at the injection site. The remaining reports (less than 15%) describe serious events, such as hospitalizations, life-threatening illnesses, or deaths. The reports of serious events are of greatest concern and receive the most careful scrutiny by VAERS staff. VAERS researchers apply procedures and methods of analysis to help them closely monitor the safety of vaccines. When a concern arises, action is taken. The hope is that this brief explanation of the factors associated with vaccines and adverse events will assist users in understanding the data they are viewing.

Vaccines protect many people from dangerous illnesses, but vaccines, like drugs, can cause side effects, a small percentage of which may be serious. VAERS is used to continually monitor reports to determine whether any vaccine or vaccine lot has a higher than expected rate of events.

About this Dataset

Data Info

Date Created

2022

Last Modified

2022-04-25

Version

2022-04-25

Update Frequency

Annual

Temporal Coverage

2022

Spatial Coverage

United States

Source

John Snow Labs; Department of Health and Human Services;

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

Vaccine Adverse Event Reporting System VAERS Data, VAERS Data, VAERS Data 2022, Vaccination Reporting System 2022, FDA Vaccine Reports, CDC Vaccine Reports, Vaccine Side Effects

Other Titles

VAERS Identification 2022, Vaccine Adverse Events 2022, Vaccine Adverse Event Reporting System VAERS Data 2022

Data Fields

Name Description Type Constraints
VAERS_Identification_NumberUnique Vaccine Adverse Event Reporting System Identification Numberintegerlevel : Nominal
Received_DateDate report was receiveddate-
State_AbbreviationState Abbreviationstring-
Age_Of_Patient_In_YearsAge of patient in years calculated by (vax_datebirthdate)numberlevel : Ratio
Age_Of_Patient_In_MonthsAge of patient in months calculated by (vax_datebirthdate). The values for this variable range from 0 to <1numberlevel : Ratio
SexGenderstring-
Date_Form_CompletedDate Form Completeddate-
Reported_SymptomDetail description for Reported symptomstring-
Is_DiedDied ('Y' = true)boolean-
Date_Of_DeathDate of Deathdate-
Is_Life_Threatening_IllnessLife-Threatening Illness ('Y' - true)boolean-
Is_Emergency_Room_Or_Doctor_VisitEmergency Room or Doctor Visit ('Y' - true)boolean-
Is_HospitalizedHospitalized ('Y' - true)boolean-
Number_Of_Days_HospitalizedNumber of days Hospitalizedintegerlevel : Ratio
Is_Prolonged_HospitalizationProlonged Hospitalization ('Y' - true)boolean-
Is_DisabilityDisability ('Y' - true)boolean-
Is_RecoveredRecovered ('Y' - true, 'N' - false)boolean-
Vaccination_DateVaccination Datedate-
Adverse_Event_Onset_DateAdverse Event Onset Datedate-
Number_Of_DaysNumber of days (Onset date - Vax. Date)integerlevel : Ratio
Diagnostic_Laboratory_DataDiagnostic laboratory datastring-
Vaccines_AdministeredVaccines Administered at (PUB=Public, PVT=Private,OTH=Other, MIL=Military, PHM=Pharmacy or drug store, SCH=School/student health clinic, SEN=Nursing home or senior living facility, WRK=Workplace clinic, UNK=Unknown)string-
Vaccines_PurchasedVaccines purchased with (PUB=Public,PVT=Private, OTH=Other, MIL=Military) fundsstring-
Other_MedicationsOther Medicationsstring-
Current_IllnessesCurrent Illnessesstring-
HistoryChronic or long-standing health conditionsstring-
Prior_Vaccination_Event_InformationPrior Vaccination Event informationstring-
SPLT_TypeManufacturer or immunization project report numberstring-
Form_VersVAERS form version 1 or 2integerlevel : Ratio
Todays_DateDate Form Completeddate-
Is_Birth_DefectCongenital anomaly or birth defect ('Y' - true)boolean-
Is_Office_VisitDoctor or other healthcare provider office or clinic visit ('Y' - true)boolean-
Is_ER_ED_VisitEmergency room or department or urgent care ('Y' - true)boolean-
AllergiesAllergies to medications, food, or other productsstring-

Data Preview

VAERS Identification NumberReceived DateState AbbreviationAge Of Patient In YearsAge Of Patient In MonthsSexDate Form CompletedReported SymptomIs DiedDate Of DeathIs Life Threatening IllnessIs Emergency Room Or Doctor VisitIs HospitalizedNumber Of Days HospitalizedIs Prolonged HospitalizationIs DisabilityIs RecoveredVaccination DateAdverse Event Onset DateNumber Of DaysDiagnostic Laboratory DataVaccines AdministeredVaccines PurchasedOther MedicationsCurrent IllnessesHistoryPrior Vaccination Event InformationSPLT TypeForm VersTodays DateIs Birth DefectIs Office VisitIs ER ED VisitAllergies
19968732022-01-01CAThis spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. Information regarding the patient's medical history, concurrent conditions or concomitant medications was not provided. On15-DEC-2021, the patient was vaccinated with an expired hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 mL injection, (lot #R017624, which was considered to be valid, expiration date: 17-MAR-2021), administered for prophylaxis (vaccination scheme frequency, anatomical location and route of administration were not provided) (expired vaccine administered). The reporter stated the vaccine did not experience any temperature excursion. No additional adverse event was reported.2021-12-152021-12-15UNKUS0095075132112USA00732022021-12-31
19968742022-01-01SUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous potential legal report received from a patient concerned a patient of unspecified age and sex. Initial information was processed along with the additional information received from a regulatory authority on 30-DEC-2021. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series: 1) (suspension for injection, route of admin not reported, batch number: Unknown and expiry: UNKNOWN) dose, start therapy date were not reported, administered 1 in total for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. It was reported that on an unspecified dates, the patient caught covid twice(coded as suspected covid-19 infection and suspected clinical vaccination failure) and reporter also stated that "If anyone is doing a class action lawsuit against these clowns, hit me up. I want in". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the suspected covid-19 infection and suspected clinical vaccination failure was not reported. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint 90000209391. The suspected product quality complaint has been confirmed to be voided(did not meet RA criteria) (as reported complaint was covid with no symptoms and test performed therefore did not meet RA criteria, hence was confirmed as voided) based on the RA evaluation/investigation performed.; Sender's Comments: V0: 20211263430 -Covid-19 vaccine ad26.cov2.s-Suspected clinical Vaccination failure. This event(s) is considered not related. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONSUNKUSJNJFOC2021126343022022-01-01
19968752022-01-01OHmaleSUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series was 1) (suspension for injection, route of admin not reported, batch number: 204A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on 11-MAY-2021 in left arm for prophylactic vaccination. No concomitant medications were reported. On 28-DEC-2021, the patient experienced feeling tired, had headaches, fever, stuffy nose, chills, body aches, nasal congestion and cough (suspected covid-19 infection). On 30-DEC-2021, Laboratory data included: COVID-19 antigen test (NR: not provided) positive (suspected clinical vaccination failure). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the suspected clinical vaccination failure and suspected covid-19 infection was not reported. This report was serious (Other Medically Important Condition). This case is associated to product quality complaint.; Sender's Comments: V0- 20211266010-Covid-19 vaccine ad26.CoV-2.s- Suspected clinical vaccination failure. This event is considered not related. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event than the drug. Specifically: SPECIAL SITUATIONS2021-12-28Test Date: 20211230; Test Name: COVID-19 antigen test; Result Unstructured Data: positiveOTHUSJNJFOC2021126601022022-01-01
19968762022-01-01MS34.0femaleIrregular menstrual cycle.; period extremely heavy; bad cramping; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. A 34 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 18Aug2021 10:00 (Lot number: Fd8448) at the age of 34 years as dose 2,single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: ZOLOFT; ORTHO-TRI-CYCLEN LO. Vaccination history included: Bnt162b2 (Dose: 1, Lot: Ew0176,, Time: 10:00 AM, vaccine location=Left arm), administration date: 28Jul2021, when the patient was 34 years old, for COVID-19 Immunization. The following information was reported: MENSTRUATION IRREGULAR (non-serious) with onset 03Sep2021, outcome "recovering", described as "Irregular menstrual cycle."; HEAVY MENSTRUAL BLEEDING (non-serious) with onset 03Sep2021, outcome "recovering", described as "period extremely heavy"; DYSMENORRHOEA (non-serious) with onset 03Sep2021, outcome "recovering", described as "bad cramping". Therapeutic measures were not taken as a result of menstruation irregular, heavy menstrual bleeding, dysmenorrhoea. Additional Information: Irregular menstrual cycle, which is very unusual for me, especially considering I am on birth control. Began period almost two weeks early, and period extremely heavy with bad cramping. Hospitalization Prolonged was reported as no. Facility where the most recent COVID-19 vaccine was administered was hospital. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.Device Date : 04Sep2021 Follow-up attempts are completed. No further information is expected.False2021-08-182021-09-0316.0PVTZOLOFT; ORTHO-TRI-CYCLEN LOComments: List of non-encoded Patient Relevant History: Patient Other Relevant History 1: None, Comment: NoneUSPFIZER INC20210116224122021-12-31
19968772022-01-01CTfemaleBreakthrough and heavy periods; longer period length; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 44 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 26Mar2021 09:00 (Lot number: EP6955) as dose 1, single and administered in arm left, administration date 19Apr2021 10:00 (Lot number: ER8731) as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ALDACTONE [SPIRONOLACTONE]. The following information was reported: HEAVY MENSTRUAL BLEEDING (non-serious) with onset 07Jun2021, outcome "not recovered", described as "Breakthrough and heavy periods"; OLIGOMENORRHOEA (non-serious) with onset 07Jun2021, outcome "unknown", described as "longer period length". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of heavy menstrual bleeding. Additional Information: Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No, prior to vaccination, was the patient diagnosed with COVID-19. Device Date: 27Sep2021. No follow-up attempts are possible. No further information is expected.False2021-03-262021-06-0773.0Test Date: 20210921; Test Name: Nasal Swab; Result Unstructured Data: Test Result:NegativePVTALDACTONE [SPIRONOLACTONE]USPFIZER INC20210128135622021-12-31
19968782022-01-0174.0maletired; Patient reports feeling achy; chills; third dose of the COVID-19 vaccine; This is a spontaneous report received from contactable reporter(s) (Other HCP and Consumer or other non HCP) for a Pfizer sponsored program. A 74 year-old male patient received bnt162b2 (BNT162B2), administration date 23Sep2021 (Batch/Lot number: unknown) at the age of 74 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: IBRANCE, start date: 23Jul2021. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTUERER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (Dose 2; MANUFACTUERER UNKNOWN), for COVID-19 immunization. The following information was reported: FATIGUE (non-serious) with onset Sep2021, outcome "recovered" (2021), described as "tired"; PAIN (non-serious) with onset Sep2021, outcome "recovered" (2021), described as "Patient reports feeling achy"; CHILLS (non-serious) with onset Sep2021, outcome "recovered" (2021), described as "chills". Additional information: Patient reports feeling achy, tired, and chills yesterday, likely due to the third dose of the COVID-19 vaccine administered 23Sep. Patient states he has no side effects today. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.True2021-09-232021-09-23UNKIBRANCEUSPFIZER INC20210128150322021-12-31
19968792022-01-01DE78.0malediarrheal discharge of both goop and intestinal matter; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 78 year-old male patient received bnt162b2 (BNT162B2), administration date 15Oct2021 (Lot number: EW0169, Expiration Date: 30Nov2021) at the age of 78 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Thyroid disorder" (unspecified if ongoing), notes: long term thyroid disorder; "Mononucleosis" (unspecified if ongoing), notes: It is Mononucleosis that did not go away.; "All muscles got stiff" (unspecified if ongoing), notes: All muscles got stiff for a couple of days, after the flu shot. It was discomforting.; "discomforting." (unspecified if ongoing), notes: All muscles got stiff for a couple of days, after the flu shot. It was discomforting. Concomitant medication(s) included: FLU, administration date Oct2021. Vaccination history included: Bnt162b2 (DOSE: 1, Batch/lot number: EW0169, Expiry date: 30Nov2021), administration date: 02Feb2021, when the patient was 77 years old, for COVID-19 immunization; Bnt162b2 (DOSE: 2, Lot number: EL9267, Expiry: 31May2021), administration date: 31May2021, when the patient was 78 years old, for COVID-19 immunization. The following information was reported: DIARRHOEA (non-serious) with onset Oct2021, outcome "recovering", described as "diarrheal discharge of both goop and intestinal matter". The event "diarrheal discharge of both goop and intestinal matter" was evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (19Oct2021) unknown result, notes: Nasal test. Therapeutic measures were taken as a result of diarrhoea. No follow-up attempts are possible. No further information is expected. Additional information: This past Friday afternoon and received booster shot for COVID vaccine. Within less than 24 hours he started to experience diarrheal discharge of both goop and intestinal matter. It continued for about a day and a half maybe two. One was to drink Gatorade and he did that and to eat bland stuff. The diarrhea, at least temporarily was discontinuing. The doctors office said to take a container with the stuff to the local clinic in (withheld). He did that this morning. They were not interested and sent him to get COVID tested and he did that. Now they tell him that he would be informed after a couple of days. He was not scheduled for an appointment with a physician today. He did not know if this is over yet. It was not very pleasant. He tried to call VAERS and the only thing they were good for sending him a form to fill out. Caller has no indication it has been reported including at the clinic. He talked with a nurse and got COVID test. It has tapered off after he drank Gatorade and did not eat very much. He has only had a couple of ripe bananas and toast over 24 hour period. And Gatorade that has no sugar. He took a couple Ricola candies and those went down ok. Prior to that he was drinking water and had cut down on medication and practically everything else. Finally he stopped passing whatever. Initially it was coming out like chocolatey goop. Then the very last one occurred last night. After most of it had dissipated, it was a couple of farts and couple of blood drops. He did not notice blood in prior discharges. It got all over everything. Once it was going to come it was going to come. It was not pleasant. From what has been said to him continuing and disabling diarrhea was not associated with booster shot yet. That was what he has heard. Loss of fluid has been pointed out to him several times as a dangerous situation. It has tapered off after he drank Gatorade and did not eat very much. Description of complaint: Caller reporting adverse event with booster shot for COVID vaccine. The reason he got it was because the first and second shot seemed to be very settling for him. With limited medical background, his impression is either the first or second may have settled and activated the immune system with the other viral complications which were documented over the years. That is a wild guess. He w as very surprised there was a reaction to this. It could be an over reaction of immune system. They sent him to get COVID nasal test. In 2 days he will get the results. If for some reason he has acquired disimmunity there will be more questions. No follow-up attempts are possible. No further information is expected.False2021-10-152021-10-01Test Date: 20211019; Test Name: COVID-19 Test; Result Unstructured Data: Test Result:Unknown result; Comments: Nasal testMILMedical History/Concurrent Conditions: Discomfort (All muscles got stiff for a couple of days, after the flu shot. It was discomforting.); Mononucleosis (It is Mononucleosis that did not go away.); Muscle stiffness (All muscles got stiff for a couple of days, after the flu shot. It was discomforting.); Thyroid disorder (long term thyroid disorder)USPFIZER INC20210140531222021-12-31True
19968802022-01-01ME56.0femaleNow Lymph node swelling in armpit closest to jab site; Exhaustion; nose running; Sore arm at jab site/jab soreness; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 56 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 17Nov2021 (Lot number: FJ1620) at the age of 56 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "gestational diabetes pre diabetes", start date: 2004 (ongoing), notes: Under control; "Haemophilia- A" (ongoing), notes: from Birth, Under control; "Pre-diabetes" (unspecified if ongoing). Concomitant medication(s) included: SIMVASTATIN taken for blood cholesterol increased, start date: 2021 (ongoing). Vaccination history included: Bnt162b2 (1st Dose, Anatomical site of injection: R upper arm, Route of administration: Intramuscular, batch/ Lot number: EW0150, 31Jul2021), administration date: 02Apr2021, when the patient was 55 years old, for Covid-19 Immunization; Bnt162b2 (2nd Dose, Anatomical site of injection: R upper arm, Route of administration: Intramuscular, batch/ Lot number: EW0176, 31Aug2021), administration date: 23Apr2021, when the patient was 55 years old, for Covid-19 Immunization. The following information was reported: IMMUNISATION (non-serious) with onset 17Nov2021, outcome "unknown", described as "Booster"; VACCINATION SITE PAIN (non-serious) with onset 17Nov2021 21:00, outcome "recovered" (19Nov2021), described as "Sore arm at jab site/jab soreness"; FATIGUE (non-serious) with onset 18Nov2021 08:00, outcome "recovered" (30Nov2021), described as "Exhaustion"; RHINORRHOEA (non-serious) with onset 18Nov2021 08:00, outcome "recovered" (21Nov2021), described as "nose running"; LYMPHADENOPATHY (non-serious) with onset 18Nov2021 10:00, outcome "recovered" (21Nov2021), described as "Now Lymph node swelling in armpit closest to jab site". Therapeutic measures were not taken as a result of vaccination site pain, fatigue, rhinorrhoea, lymphadenopathy. Additional Information: Prior Vaccinations (within 4 weeks): None, Specific relevant tests for thromboembolic events with thrombocytopenia :None. Vaccination Facility Type was PHARMACY, Vaccine was not Administered at Facility. Route of Simvastatin: By Mouth and taken in early 2021. Event: Sore arm at jab site. Exhaustion and nose running began approximately 20 hrs later. Description of Event: Part 2 - yesterday I submitted exhaustion and jab soreness. Now Lymph node swelling in armpit closest to jab site. Follow-up attempts are completed and no further information is expectedTrue2021-11-172021-11-17PHMSIMVASTATINGestational diabetes (Under control); Haemophilia A (from Birth Under control)Medical History/Concurrent Conditions: Pre-diabetesUSPFIZER INC20210163143622021-12-31
19968812022-01-01NYmy torso was covered with a rash/rash spreadof over my entire body/she developed widespread, sevre erythrodermic skin eruption; She had skin biopsy conforming lichenoid drug eruption; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Other HCP) for a Pfizer sponsored program. The reporter is the patient. A patient (no qualifiers provided) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 14Apr2021 13:00 (Lot number: ER8731) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Anxiety /Depression", start date: 2009 (ongoing); "Anxiety /Depression", start date: 2009 (ongoing); "Hysterectomy", start date: 2011 (unspecified if ongoing), notes: Pertinent details: Hysterectomy. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose:1, single, Time:01:00 PM, Anatomical site of injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: ER2613), administration date: 24Mar2021, for COVID-19 Immunization. The following information was reported: RASH (medically significant) with onset Apr2021, outcome "recovered" (2021), described as "my torso was covered with a rash/rash spreadof over my entire body/she developed widespread, sevre erythrodermic skin eruption"; DRUG ERUPTION (non-serious) with onset 2021, outcome "unknown", described as "She had skin biopsy conforming lichenoid drug eruption". The event "my torso was covered with a rash/rash spreadof over my entire body/she developed widespread, sevre erythrodermic skin eruption" was evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: biopsy: (2021) having a reaction to a medication, notes: A biopsy was taken from my skin is and it was determined I was having a reaction to a medication; biopsy skin: (23Sep2021) lichenoid dermatitis, notes: Lichenoid Dermatitis, compatible with lichenoid drug eruption. Therapeutic measures were taken as a result of rash.True2021-04-142021-04-01Test Date: 2021; Test Name: biopsy; Result Unstructured Data: Test Result:having a reaction to a medication; Comments: A biopsy was taken from my skin is and it was determined I was having a reaction to a medication.; Test Date: 20210923; Test Name: Skin Punch Biopsy; Result Unstructured Data: Test Result:Lichenoid Dermatitis; Comments: Lichenoid Dermatitis, compatible with lichenoid drug eruptionOTHAnxiety; DepressionMedical History/Concurrent Conditions: Hysterectomy (Pertinent details: Hysterectomy)USPFIZER INC20210163976222021-12-31True
19968822022-01-0171.0malepyrexia; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). A 71 year-old male patient received bnt162b2 (COMIRNATY), administration date Jan2021 (Batch/Lot number: unknown) at the age of 71 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PYREXIA (non-serious), outcome "unknown", described as "pyrexia". Additional information: the patient didn't get any pain after the first dose. It was only after the second dose. Caller doesn't recall patient having any severe reactions with either dose. Patient had some pyrexia, the usual things that a person gets after the first and second dose. Patient was not really sick. Thinks patient got chills and fever and it went away. Nothing that caller would think was unusual. Attempted to clarify dates regarding fever, pyrexia, and chills. Caller doesn't know when this occurred or after which dose. Caller just remembers patient saying he was going to bed because he was cold. Attempted to clarify dates of Comirnaty vaccines: Caller had her first dose in Dec2020 and second dose in Jan2021. She thinks the patient had his first dose in middle of Jan2021 and second dose in Feb2021. Caller does not have patient's record card to provide any information about patient's Comirnaty vaccines. Indication: Both caller and the patient are in the medical field. They both see patients. Patient still walks around like he was a man from Mars. A couple months later, caller has not seen patient put the Volatren on. States it's regular. Patient mentioned recently that he should see someone about the pain, which was unlike him. Caller thinks the pain must be bothering the patient significantly. Caller doesn't know if patient was having pain or if patient was frustrated. Caller decided on her own to call and report this to Pfizer. Patient had the booster dose just recently. Doesn't believe patient's pain has gotten any worse since the booster shot, but she hasn't actually asked the patient that. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.2021-01-01UNKUSPFIZER INC20210164990322021-12-31